Betta Pharmaceuticals Valuation
| 300558 Stock | 52.69 1.11 2.06% |
At this time, the firm appears to be overvalued. Betta Pharmaceuticals shows a prevailing Real Value of USD40.71 per share. The current price of the firm is USD52.69. Our model approximates the value of Betta Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 24.03 B, profit margin of 0.17 %, and Return On Equity of 0.0804 as well as examining its technical indicators and probability of bankruptcy.
Price Book 3.9941 | Enterprise Value 24 B | Enterprise Value Ebitda 47.4438 | Price Sales 8.3324 | Trailing PE 50.367 |
Overvalued
Today
Please note that Betta Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Betta Pharmaceuticals is based on 3 months time horizon. Increasing Betta Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Betta Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Betta Stock. However, Betta Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 52.69 | Real 40.71 | Hype 53.11 |
The real value of Betta Stock, also known as its intrinsic value, is the underlying worth of Betta Pharmaceuticals Company, which is reflected in its stock price. It is based on Betta Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Betta Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Betta Pharmaceuticals Co helps investors to forecast how Betta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Betta Pharmaceuticals more accurately as focusing exclusively on Betta Pharmaceuticals' fundamentals will not take into account other important factors: Betta Pharmaceuticals Cash |
|
Betta Pharmaceuticals Total Value Analysis
Betta Pharmaceuticals Co is presently forecasted to have takeover price of 24.03 B with market capitalization of 22.97 B, debt of 300.27 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Betta Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
24.03 B | 22.97 B | 300.27 M |
Betta Pharmaceuticals Investor Information
About 48.0% of the company shares are owned by insiders or employees . The book value of Betta Pharmaceuticals was presently reported as 13.47. The company last dividend was issued on the 6th of June 2024. Based on the key indicators related to Betta Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Betta Pharmaceuticals Co is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 959.9 M | 914.2 M |
|
| |||||
| Operating Income | 285.1 M | 332.1 M |
|
|
Betta Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Betta Pharmaceuticals has an asset utilization ratio of 26.85 percent. This suggests that the Company is making USD0.27 for each dollar of assets. An increasing asset utilization means that Betta Pharmaceuticals Co is more efficient with each dollar of assets it utilizes for everyday operations.Betta Pharmaceuticals Ownership Allocation
Betta Pharmaceuticals holds a total of 418.49 Million outstanding shares. Betta Pharmaceuticals Co retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Betta Pharmaceuticals Profitability Analysis
The company reported the revenue of 2.46 B. Net Income was 348.03 M with profit before overhead, payroll, taxes, and interest of 2.07 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Betta Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Betta Pharmaceuticals and how it compares across the competition.
About Betta Pharmaceuticals Valuation
The stock valuation mechanism determines Betta Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Betta Pharmaceuticals. We calculate exposure to Betta Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Betta Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.1 B | 1.6 B |
Betta Pharmaceuticals Quarterly Retained Earnings |
|
Complementary Tools for Betta Stock analysis
When running Betta Pharmaceuticals' price analysis, check to measure Betta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Betta Pharmaceuticals is operating at the current time. Most of Betta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Betta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Betta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Betta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |